These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28239762)

  • 1.
    Sounier R; Yang Y; Hagelberger J; Granier S; Déméné H
    Biomol NMR Assign; 2017 Apr; 11(1):117-121. PubMed ID: 28239762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical shift assignments of a camelid nanobody against aflatoxin B
    Nie Y; Li S; Zhu J; Hu R; Liu M; He T; Yang Y
    Biomol NMR Assign; 2019 Apr; 13(1):75-78. PubMed ID: 30328057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of Nanobody Nb23.
    Percipalle M; Hunashal Y; Steyaert J; Fogolari F; Esposito G
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications.
    Yu X; Xu Q; Wu Y; Jiang H; Wei W; Zulipikaer A; Guo Y; Jirimutu ; Chen J
    Biomater Sci; 2020 Jul; 8(13):3559-3573. PubMed ID: 32490444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on camelid nanobodies with potential application in veterinary medicine.
    Tohidi E; Ghaemi M; Golvajouei MS
    Vet Res Commun; 2024 Aug; 48(4):2051-2068. PubMed ID: 38869749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Nanobodies.
    Muyldermans S
    Annu Rev Anim Biosci; 2021 Feb; 9():401-421. PubMed ID: 33233943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
    Lecocq Q; Zeven K; De Vlaeminck Y; Martens S; Massa S; Goyvaerts C; Raes G; Keyaerts M; Breckpot K; Devoogdt N
    Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel nanobody-based bio-assay using functional complementation of a split nanoluciferase to monitor Mu- opioid receptor activation.
    Vasudevan L; Stove CP
    Anal Bioanal Chem; 2020 Nov; 412(29):8015-8022. PubMed ID: 32926202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobodies to Study G Protein-Coupled Receptor Structure and Function.
    Manglik A; Kobilka BK; Steyaert J
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():19-37. PubMed ID: 27959623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camelid nanobodies: killing two birds with one stone.
    Desmyter A; Spinelli S; Roussel A; Cambillau C
    Curr Opin Struct Biol; 2015 Jun; 32():1-8. PubMed ID: 25614146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of mWasabi fluorescent protein-binding nanobodies.
    Li S; Shan H; Wang T; Zheng X; Shi M; Chen B; Lu H; Zhang Y; Zhao S; Hua Z
    Anal Biochem; 2020 Nov; 608():113875. PubMed ID: 32739350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor.
    Livingston KE; Mahoney JP; Manglik A; Sunahara RK; Traynor JR
    Elife; 2018 Jun; 7():. PubMed ID: 29932421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (1)H, (13)C and (15)N assignments of a camelid nanobody directed against human alpha-synuclein.
    Vuchelen A; O'Day E; De Genst E; Pardon E; Wyns L; Dumoulin M; Dobson CM; Christodoulou J; Hsu ST
    Biomol NMR Assign; 2009 Dec; 3(2):231-3. PubMed ID: 19763886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli.
    Oyen D; Wechselberger R; Srinivasan V; Steyaert J; Barlow JN
    Biochim Biophys Acta; 2013 Oct; 1834(10):2147-57. PubMed ID: 23911607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobody-enabled monitoring of kappa opioid receptor states.
    Che T; English J; Krumm BE; Kim K; Pardon E; Olsen RHJ; Wang S; Zhang S; Diberto JF; Sciaky N; Carroll FI; Steyaert J; Wacker D; Roth BL
    Nat Commun; 2020 Mar; 11(1):1145. PubMed ID: 32123179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yeast surface display platform for rapid discovery of conformationally selective nanobodies.
    McMahon C; Baier AS; Pascolutti R; Wegrecki M; Zheng S; Ong JX; Erlandson SC; Hilger D; Rasmussen SGF; Ring AM; Manglik A; Kruse AC
    Nat Struct Mol Biol; 2018 Mar; 25(3):289-296. PubMed ID: 29434346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobodies as Probes for Protein Dynamics in Vitro and in Cells.
    Dmitriev OY; Lutsenko S; Muyldermans S
    J Biol Chem; 2016 Feb; 291(8):3767-75. PubMed ID: 26677230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INDI-integrated nanobody database for immunoinformatics.
    Deszyński P; Młokosiewicz J; Volanakis A; Jaszczyszyn I; Castellana N; Bonissone S; Ganesan R; Krawczyk K
    Nucleic Acids Res; 2022 Jan; 50(D1):D1273-D1281. PubMed ID: 34747487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.
    Staus DP; Strachan RT; Manglik A; Pani B; Kahsai AW; Kim TH; Wingler LM; Ahn S; Chatterjee A; Masoudi A; Kruse AC; Pardon E; Steyaert J; Weis WI; Prosser RS; Kobilka BK; Costa T; Lefkowitz RJ
    Nature; 2016 Jul; 535(7612):448-52. PubMed ID: 27409812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.